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Abstract
Epigenetic silencing of tumor suppressor genes (TSGs) through DNA methylation and histone changes is a
main hallmark of cancer. Ubiquitin-like with PHD and RING Finger domains 1 (UHRF1) is a potent oncogene
overexpressed in various solid and haematological tumors and its high expression levels are associated with
decreased expression of several TSGs including p16INK4A, BRCA1, PPARG and KiSS1. Using its several functional
domains, UHRF1 creates a strong coordinated dialogue between DNA methylation and histone post-translation
modification changes causing the epigenetic silencing of TSGs which allows cancer cells to escape apoptosis. To
ensure the silencing of TSGs during cell division, UHRF1 recruits several enzymes including histone deacetylase 1
(HDAC1), DNA methyltransferase 1 (DNMT1) and histone lysine methyltransferases G9a and Suv39H1 to the right
place at the right moment. Several in vitro and in vivo works have reported the direct implication of the epigenetic
player UHRF1 in tumorigenesis through the repression of TSGs expression and suggested UHRF1 as a promising target
for cancer treatment. This review describes the molecular mechanisms underlying UHRF1 regulation in cancer and
discusses its importance as a therapeutic target to induce the reactivation of TSGs and subsequent apoptosis.
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Background
Beside genetic alterations in cancer cells, epigenetic
changes (DNA methylation and histone modifications)
can also induce silencing of tumor suppressor genes
allowing cancer cells to escape apoptosis and promote
tumor progression [1–4]. The epigenetic reader UHRF1
(Ubiquitin-like, containing PHD and RING Finger
domains 1), an oncogene overexpressed in various
human cancer cells is one of the major players involved
in apoptosis inhibition by inducing epigenetic silencing
of TSGs [5–8]. UHRF1 has several functional domains
(Fig. 1): UBL (ubiquitin-like) domain, TTD (Tandem
Tudor Domain), PHD (Plant Homeo Domain) domain,
SRA (Set and Ring Associated) domain and RING
(Really Interesting New Gene) domain. Through these
domains, UHRF1 interacts with various proteins, form-
ing a large macro-molecular protein complex called
ECREM « Epigenetic Code Replication Machinery »,
which is engaged in the transmission of the epigenetic
code including the silencing of TSGs, from a mother
cancer cell to daughter cells during cell proliferation
[5, 6]. By its original structure, UHRF1 might be the
driver of this complex to ensure the replication of the
epigenetic code (DNA methylation and histone code)
after DNA replication, allowing cancer cells to con-
serve the silencing of TSGs during cell division. The
SRA domain of UHRF1 behaves as a “hand” with two
fingers that serve to flip out the methylated cytosine
with subsequent recruitment of DNMT1 to methylate the
cytosine of the newly synthetized DNA strand [9–11].
This recruitment was proposed to be under the control of
SRA binding to hemi-methylated DNA, challenging
enhanced activity of the UHRF1 RING finger that exhibits
E3 ligase activity towards histone H3 [12, 13]. The TTD
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exhibits affinity for methylated histones and allows to
confer a fabulous property to UHRF1 of connecting DNA
methylation to histone modifications [14, 15]. Recently,
new insights have been gained into the mechanism of this
connection. Indeed, Fang et al., showed how UHRF1 can
coordinately recognize histone modifications and hemi-
methylated DNA [16]. UHRF1 adopts a closed conform-
ation, in which a spacer located in the C-terminal region
of UHRF1 binds to the TTD and thus hinders this latter
from H3K9me3 binding [16]. The SRA domain binds to
the PHD and inhibits this latter from H3R2 recognition.
In the presence of hemi-methylated DNA, the intramo-
lecular interactions were impaired thanks to a preferred
affinity for hemi-methylated DNA vs PHD domain. Subse-
quently, H3K9me3 recognition by TTD–PHD is facilitated
and thus is supporting a crucial role for UHRF1 in con-
necting DNA methylation with histone post-translational
modifications. The close conformation has been recently
proposed as being regulated by phosphatidyl-5-phosphate
[17], a small molecule involved in cell signaling and cell
traffic [18]. The authors suggested that phosphatidyl-5-
phosphate, since its concentration is varying from G1 to S
phase, might determine the localization of UHRF1 in
chromatin during the cell cycle [17]. Consistently with
these studies, the contribution of UHRF1 to the intercon-
nection between DNA methylation and histone methyla-
tion has been further deciphered by a new study, which
supports a model in which H3K9 methylation recognition,
through the TTD domain, while not essential, promotes
DNA methylation maintenance [19].
Recently, new highly interesting functions were uncov-
ered for UHRF1. One of the most interesting is a sensor
role for interstrand crosslinks, showing that UHRF1 is
also involved in DNA repair processes [20–22]. Of note,
it was also shown that the decrease of UHRF1 protein
levels is a major cause of DNA demethylation in embry-
onic stems cells [23]. Therefore, UHRF1 appears to have
a triple role during cell proliferation, i.e., in DNA methy-
lation pattern inheritance, sensor of DNA crosslinks and
a facilitator of DNA demethylation during development.
It is thus easily conceivable that a dysregulation of one
or more of these functions may lead to genomic alter-
ation and thus to cancer.
Considering the fact that UHRF1 is overexpressed in
various solid [5, 24] and haematological tumors [25, 26]
and that UHRF1 via its domains (Fig. 1) guarantees a
strong relationship between DNA methylation and his-
tone post-translational changes [5, 6, 27, 28], targeting
this epigenetic actor could be a new promising antican-
cer strategy. In this review, we highlight the role of
UHRF1 in the epigenetic silencing of TSGs and the
molecular mechanisms underlying UHRF1 regulation in
cancer cells as well as the increasing importance of
UHRF1 as a promising target for anticancer therapy.
Role of UHRF1 in the epigenetic silencing of TSGs
in cancer
Several TSGs, among which p16INK4A seems to be the
most interesting, were shown as being silenced through
UHRF1-mediated epigenetic modifications, mainly DNA
methylation [6, 29]. The tumor suppressor gene
p16INK4A is involved in the G1/S cell cycle checkpoint
and its lost expression leads to apoptosis inhibition,
enhanced cell proliferation and loss of cell contact inhib-
ition. UHRF1 uses its functional domains to exert epi-
genetic inhibitory effects on TSGs including p16INK4A
[30–32]. Indeed, one of the most important features of
UHRF1’s structure, is the presence of an intriguing “Set
and Ring Associated” domain (SRA), which is found only
in the UHRF family [5]. Using its SRA domain, UHRF1
interacts with histone deacetylase 1 (HDAC1) and
DNMT1 [7, 31, 33]. This interaction takes place at
methylated promoter regions of several TSGs including











Fig. 1 Schematic representation of UHRF1 structure and its role in the regulation of epigenetic code. Abbreviation: UBL (ubiquitin-like) domain,
TTD (Tandem Tudor Domain), PHD (Plant Homeo Domain) domain, SRA (Set and Ring Associated) domain and RING (Really Interesting New
Gene) domain. RING domain has an E3 ligase activity involved in UHRF1 autoubiquitination. UHRF1 is protected from this process by its
interaction with herpes virus-associated ubiquitin-specific protease (HAUSP). Through its SRA domain, UHRF1 recognizes hemi-methylated DNA
during DNA replication and interacts with DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1). UHRF1 can also interact with
DNMT1 via its PHD domain. Both PHD and TTD are involved in the readout of histone methylation that are catalysed by histone methyltransferases
G9a and Suv39H1. The UBL domain could be involved in the proteasome pathway
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encoded by the CDKN2A gene [34], and RARalpha [7].
However, to our knowledge no data are so far available
in the literature about the consequence on p14ARF and
RAR protein levels [7]. Interestingly, UHRF1 depletion
resulted in DNMT1 downregulation and an upregulation
of p16INK4A [31]. In the same context, we have shown
that the natural anti-cancer drug, epigallocatechin-3-
gallate (EGCG) induces a significant decrease in UHRF1
and DNMT1 expression in Jurkat cells in association
with p16INK4A upregulation, cell cycle G1/S arrest and
apoptosis [32]. The EGCG-induced p16INK4A upregula-
tion was related to a significant decrease in UHRF1 pro-
tein binding to p16INK4A promoter [32]. Interestingly,
wild type UHRF1 overexpression, but not SRA UHRF1
mutants, was able to decrease p16INK4A expression indi-
cating that UHRF1 negatively controls the expression of
p16INK4A in leukemia cells [32]. It appears that p16INK4A
upregulation through a UHRF1 downregulation is a key
mechanism of many natural drugs exhibiting anti-cancer
properties [9, 29, 32].
UHRF1 was also shown to be overexpressed in colo-
rectal cancer (CRC) and its overexpression is associated
with CRC progression [35]. In this type of cancer,
UHRF1 knockdown induced an upregulation of
p16INK4A, inhibition of cell proliferation and metastasis
as well as apoptosis [35]. UHRF1 was also shown to be
overexpressed in primary non-small cell lung cancer
(NSCLC) and its high expression level was associated
with an increase in the expression of DNMT1,
DNMT3A, and DNMT3B and correlated with hyperme-
thylation of p16INK4A promoter [36]. In accordance with
this, enhanced UHRF1 expression was also reported in
gastric cancer (GC), and correlated with tumor progres-
sion [37]. Again, UHRF1 depletion induced the reactiva-
tion of several TSGs, including p16INK4A, and led to cell
proliferation inhibition [37]. Recently, we showed that
activation of CD47 in two human astrocytoma cell lines,
upregulated the expression of UHRF1 with subsequent
downregulation of p16INK4A [38]. All these studies sup-
port the existence of a common mechanism in cancer
that UHRF1 regulates the expression of p16INK4A with
subsequent inhibition of the apoptotic pathways. It is
also noteworthy that UHRF1 regulates a plethora of
other TSGs among which RB1 especially in Jurkat and
osteosarcoma cells [31, 39, 40], CDX2, CDKN2A, RUNX3,
FOXO4, PPARG, BRCA1 and PLM, in gastric cancer [37],
SOCS3 and 3OST2 in endometrial carcinoma [41] as well
as BRCA1 in cancer breast cell lines [42].
The overall well admitted mechanism of tumor sup-
pressor gene silencing is thought to be DNA methylation
as almost all promoters of TGS regulated by UHRF1 are
hypermethylated. Note that UHRF1 is also able to
silence, in DNA methylation dependent process, KiSS1,
a gene known to have anti-metastasis functions [43].
However, it has not to be neglected that other mecha-
nisms might be involved such as histone post-translational
modifications. Indeed, considering that UHRF1 has several
histone modifyers as partners, all these may putatively
exert a contribution in the definitive interlocking of TSGs.
For instance, UHRF1 has been shown to recruit histone
lysine methyltransferase G9a to the BRCA1 promoter and
with subsequent histone 3 lysine 9 methylation [42]. In
another study, it has been reported that UHRF1 associates
with PRMT5 (Protein arginine N-methyltransferase 5) in
endometrial carcinoma [44]. In the same study, it has been
shown that the promoters of TSGs CH13 and SHP1 were
hypermethylated but whether there is a link between the
activity of PRMT5 and TSGs silencing still remains elu-
sive. But if it is the case, it would mean that UHRF1, by
recruiting PRMT5 to the TSGs promoters, favors the
participation of the dimethylation of arginine 8 of histone
H3 (H3R8me2) and arginine 3 of histone H4 (H4R3me2)
to gene silencing of TSGs ST7 and RBL2 [45]. Whilst
these possibilities cannot and should not be discounted, it
is worth pointing out that the complexity of UHRF1-
dependent TSGs regulation might be as directly propor-
tional to the size of the macromolecular UHRF1 complex.
One important member of this macromolecular com-
plex is USP7 (Ubiquitin Specific Peptidase 7) or HAUSP
(Herpes virus-Associated Ubiquitin-Specific Protease).
HAUSP has been reported to regulate several TSGs,
including p53 [46]. The deubiquitinase HAUSP was
shown to interact with UHRF1 to maintain its deubiqui-
tination status protecting it from autoubiquitination and
degradation by the proteasome [47–49]. Overexpression
of HAUSP increased UHRF1 level while HAUSP down-
regulation induced UHRF1 ubiquitination causing its
degradation via a proteasome-dependent process [48].
These findings indicate that HAUSP acts as a UHRF1
protector from autoubiquitination-mediated degrad-
ation using RING domain [48]. Recently, it has been
shown that HAUSP controls the stability of UHRF1 not
only by maintaining its deubiquitination, but also by
promoting its chromatin association [50]. Indeed, HAUSP
was shown to reduce the E3 ligase activity (autoubiquiti-
nation) of wild-type UHRF1 but not in the UHRF1 K659E
mutant, disturbing the UHRF1 domain involved in its
interaction with HAUSP [50]. Interestingly, HAUSP inter-
action with UHRF1 facilitated its binding to the H3K9me3
and induced a significant increase in its association with
chromatin in the cervical cancer cell line Hela-60 [50].
Taken together, these data show that HAUSP has a dual
regulatory role of UHRF1, by protecting it from autou-
biquitination (Fig. 1) and by facilitating its association
to the chromatin through the readout of the histone
code. Therefore, HAUSP tandem may control TSGs
expression via UHRF1 mediated by a ubiquitination/
deubiquitination balance and might be further considered
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as a key mechanism involved in controlling cell prolifera-
tion and apoptosis [51].
A regulatory influence on TSGs by UHRF1 might also
be mediated independently of DNA methylation, for in-
stance through an enzymatic partner. Indeed, it has been
demonstrated that UHRF1 inhibits the interplay between
Tip60 and p53 [52]. Tip60, an essential partner of UHRF1
[53], acetylates p53 at K120 to induce apoptosis [54]. It
was suggested that increased expression of UHRF1 found
in cancer might be responsible for decreased activity of
p53 and apoptosis failure in tumors [52].
All these findings indicate that UHRF1 is a main key in
the epigenetic silencing of various TSGs in cancer. So, un-
derstanding the molecular mechanisms underlying UHRF1
overexpression in cancer will help to find new targets to
inhibit UHRF1 expression which will allow cancer cells to
undergo apoptosis through the reactivation of silenced
TSGs. In other words, the goal would be to re-express
TSGs in cancer cells to allow them to commit “suicide” via
a re-activation of the apoptotic pathways.
Signalling pathways involved in UHRF1 regulation
in cancer cells
Role of TSGs in UHRF1 regulation
The tumor suppressor gene p53 is involved in control-
ling cell cycle at G1/S transition ensuring a successful
cell division [55, 56]. p53 is silenced in 50 % of human
cancers causing loss of cell cycle G1/S checkpoints
which allows cancer cells to escape apoptosis [57–59]. In
contrast to p53, p73, a p53 functional and structural
homolog [60], is rarely mutated in cancer [61]. UHRF1
has been shown to be targeted by TSGs such p53 and
p73 [62–64] suggesting that UHRF1 overexpression
observed in many human cancer could result from
abnormal TSGs expression or from non-functional
TSGs. We have shown that thymoquinone (TQ) triggers
apoptosis in the p53-deficient Jurkat cell line through
the activation of p73 [63]. Interestingly the depletion of
p73 in TQ-treated cells prevented UHRF1 from TQ-
induced degradation, indicating that p73 negatively con-
trols the expression of UHRF1 [63]. In the same context,
UHRF1 expression was shown to be decreased by p53
upregulation as a response to anticancer drugs-induced
DNA damage [62]. Taken together, these findings sug-
gest that UHRF1 expression levels observed in cancer
could result from defects in the expression of some
TSGs such as p53 and p73. Thus, UHRF1 is regulated by
TSGs expression but by a feed-back mechanism can also
control the activity of TSGs.
Regulation of UHRF1 by miRNA
microRNAs (miRNAs: 18–25 nucleotides) are consid-
ered as negative regulators for several genes at the post-
transcriptional level [65, 66]. These small noncoding
RNAs exert their action by binding to the 3′-untranslated
region (3′-UTR) of their target mRNA resulting in deg-
radation of mRNA from more than 60 % of human genes
[67–69]. Depending on the cellular function of miRNAs
targets, these molecules could be either an oncogene or a
tumor suppressor gene [70]. Moreover, several studies
revealed a strong relationship between many cancers and
either mutations or abnormalities in miRNAs expression
[70, 71]. In this context, it has been shown that miR-206
acts as a tumor suppressor able to inhibit the expression
of both oncogenes c-Met and Bcl2, that are overexpressed
in various cancers including lung cancer [72]. miR-720
expression was shown to be significantly reduced in acute
myeloid leukemia (AML) patients compared to normal
controls, while its overexpression induced an upregulation
of tumor suppressor p53 leading to cell proliferation
inhibition and apoptosis [73].
Considering the fact that UHRF1 overexpression, ob-
served in cancer, is associated with decreased expression
levels of several miRNAs which act as tumor suppressor
genes, it can be thus speculated that the large quantities
of the UHRF1 produced in tumors might result from
abnormalities in the expression of miRNA. In agreement
with this, it has been shown that UHRF1 overexpression
in GC results from a reduction in the expression of
miR-146a and miR-146b, which are known to act as
tumor suppressors in GC [74]. Interestingly, miR-146a/b
overexpression significantly decreased UHRF1 expres-
sion by directly targeting its binding sites (3′-UTR)
triggering DNA demethylation-dependent reactivation of
some TSGs such as RUNX3 [74]. Reduction in GC
migration and in metastasis were the consequences [74].
In contrast, the downregulation of miR-146a/b induced
an increase in UHRF1 expression, further and defini-
tively confirming that miR-146a/b negatively regulates
the expression of UHRF1 in GC [74].
miR-9 acts as tumor suppressor in CRC and its
expression has been observed to be decreased in CRC
compared to corresponding normal tissues [75, 76].
UHRF1 expression was shown to be more pronounced
in human CRC tissue than matched normal tissues and
its overexpression was linked to decreased expression
levels of miR-9 and reduced survival rates of CRC
patients [77]. Interestingly, transfection of CRC cells by
pre-miR-9 induced a significantly decrease in UHRF1
expression indicating that pre-miR-9 negatively controls
UHRF1 expression and that UHRF1 overexpression in
CRC may result from a decrease in the expression of
miR-9 [77].
The tumor suppressor, miR-193a-3p, has been re-
ported to inhibit NSCLC progression but the molecular
pathways through which this miRNA induces its inhibi-
tory effects are largely unknown [78]. Nevertheless, it
has been recently observed that miR-193a-3p repressed
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the metastasis of lung cancer cells by targeting several
proteins highly expressed in NSCLC including UHRF1
[79] indicating that miR-193a-3p negatively modulates
the expression of UHRF1 in NSCLC. In the same way,
the tumor suppressor gene, miR-145-5p and 145-3p as
well, were shown to down-regulate UHRF1 in bladder
cancer, with subsequent apoptosis by targeting genes
such as BIRC5 and CENPF [80]. The regulatory mechan-
ism involves a direct targeting of miRNA to the 3′-UTR
of UHRF1 mRNA. Interestingly, in this study UHRF1
was reported to be upregulated in bladder cancer clinical
specimens and to promote anti-apoptotic effects through
regulation of several oncogenic genes [80]. Finally, it was
suggested that UHRF1 might be a useful prognostic
marker for survival of bladder cancer patients [80]. More
recently UHRF1 has been shown to be regulated by
miR-101 in renal cell carcinoma [81].
miR-34a acts as a tumor suppressor in various cancers
and its decreased expression levels were suggested to
play a causal role in the initiation and progression of the
tumor [82, 83]. Recently, it has been shown that TQ-
encapsulated nanoparticles induce apoptosis in cancer
cells by increasing the expression of miR-34a through
p53-dependent pathway [84]. TQ, the most abundant
biologically active component of black cumin oil, has
potent anticancer activities on many human cancer cell
lines by targeting numerous signalling pathways involved
in the regulation of cell cycle and apoptosis including p53
and p73 pathways [29, 63, 85]. Considering that TQ
targets UHRF1 in p53-mutated Jurkat cells through p73-
dependent pathway [63] and that UHRF1 is also regulated
by p53 [62], we might imagine that TQ decreases the
expression of UHRF1 in cancer cells through the upregu-
lation of miR-34a. Taken together, all these findings show
that miRNAs exert a fine tuning of tumor-suppressor
expression via regulation of UHRF1 expression (Fig. 2).
Regulation of UHRF1 by CD47/ NF-ĸB pathway
Cancer cells use several strategies to escape immune
system control. CD47, also called integrin-associated
protein, is an immunoglobulin protein found on the
surface of many human cells [86, 87]. Through its extra-
cellular domain, CD47 exerts phagocytosis inhibitory
activities via its ligation to the inhibitory receptor SIRPα
(signal regulatory protein alpha) expressed on macro-
phages [88, 89]. Both solid and haematological tumors
cells produce high amount of CD47 protein on their
surface, compared with normal cells [90, 91]. CD47
overexpression is used by cancer cells to escape from the
macrophages-mediated “don’t eat me” signal allowing
tumor to progress [92–94]. Blocking the CD47/SIRPα
axe-mediated “don’t eat me” signal allow macrophages
to recognize CD47-positive cancer cells with subse-
quently destroy and elimination through a phagocytosis
process [93, 95]. Several strategies have been used to
target CD47 in cancer therapy. For instance, blocking
CD47 function, using monoclonal antibodies against the
CD47/SIRPα, showed in vitro and in vivo an important
impact in many tumors overproducing CD47, such as
leukemia and glioblastoma [94, 96]. It has been shown
that CD47 is overexpressed in human melanoma and its
depletion using CD47 siRNA significantly inhibited mel-
anoma growth and metastasis [97]. In the same way,
CD47 knockdown using specific siRNA inhibited the
migration of intestinal epithelial cell by reducing the
expression of cyclooxygenase-2 (COX-2) [98]. Recently,
we showed that CD47 activation using 4 N1 (CD47
agonist) peptide induced a significant increase in the
expression of both UHRF1 gene and protein in human
astrocytoma cell lines U87 and CCF-STTG1 (Grade IV)
without affecting their expression in normal human
astrocytes NHA [38]. The enhancement of UHRF1
expression induced by CD47 activation was associated
with the phosphorylation of IĸBα, a NF-ĸB inhibitor,
downregulation of p16INK4A and enhancement of cell
proliferation [38]. In contrast, antagonizing CD47 function
using monoclonal antibody (B6H12) induced downregula-
tion of UHRF1 accompanied by dephosphorylation of
IĸBα, an upregulation of p16INK4A and decreased cell pro-
liferation [38]. Interestingly, CD47 knockdown using
siRNA in U87 cell line induced a significant downregula-
tion of UHRF1 indicating that CD47 positively controls
the expression of UHRF1 in glioblastoma cells [38].
The transcription factor NF-ĸB is activated in many
human cancer including brain tumors [99, 100]. Consid-
ering that CD47-induced IĸBα phosphorylation was
associated with UHRF1 upregulation and increased cell
proliferation [38] and that CD47 activation induced the
phosphorylation of Akt [101], we suggest that CD47
activation increases UHRF1 expression and promotes
cell proliferation through the activation of the Akt-
dependent NF-ĸB pathway (Fig. 3). Furthermore, we
hypothesise that CD47 activation leads to IĸBα phos-
phorylation, thus releasing the active NF-ĸB complex
(p50 and p65) which translocates into nucleus (Fig. 3a).
p50 or p65 then binds to UHRF1 promoter inducing its
activation and subsequently inhibits p16INK4A expression
via UHRF1 binding to the promoter of this latter,
promoting thus cell proliferation and metastasis (Fig. 3a).
In contrast, CD47 function blocking will inhibit NF‐κB
transactivation leading to decrease in NF‐κB binding to
UHRF1 promoter thereby inhibiting cell proliferation
through p16INK4A reactivation (Fig. 3b). These findings
indicate a key role of CD47 receptor in the regulation of
UHRF1 expression most likely through the activation of
the NF-ĸB pathway and also suggest that the overexpres-
sion of UHRF1 observed in many human cancers might
result from high levels of cell plasma membrane CD47.
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Regulation of UHRF1 by TRα1/Sp1 pathway
The thyroid hormone T3 (3,5,3′-triiodo-L-thyronine) is
an important regulator of development, metabolism and
cell proliferation [102]. The thyroid hormone receptors
(TRs) act as tumor suppressors and their abnormal ex-
pression can lead to cancer progression [103]. T3 binds
to TR regulating the expression of various genes includ-
ing those involved in cell proliferation [103]. In this con-
text, it has been shown that T3 negatively regulates the
expression of UHRF1 in hepatoma cell line, which highly
overexpresses TRα1 [104]. UHRF1 was shown to be
overexpressed in liver cancer patients and its overex-
pression was accompanied with the size of tumor [104].
Exposure of TR-expressing HepG2 cells to T3 decreased
the levels of UHRF1 mRNA and protein compared to
TR-muted HepG2 [104]. T3-induced UHRF1 downregu-
lation was associated with a decreased level of the tran-
scription factor Sp1, upregulation of p21, G0/G1 cell
miR-146a/b miR-9 miR-193a-3p 
Inhibition of cell proliferation and metastasis
-UTR of UHRF1 
TSGs
(p16INK4A, BRCA1, PPARG and KiSS1)




Wild type p53 cancer cells  
miR-34a TQp53
UHRF1 
Fig. 2 Schematic model of the role of miRNA in UHRF1 regulation in cancer cells. Several miRNAs act as tumor-suppressor by binding to the
3′-untranslated region (3′-UTR) of mRNA UHRF1 leading to its degradation. TQ increases the expression of miR-34a which leads to upregulation
of p53 in wild type p53 cancer cells or p73 in p53-mutated cancer cells with subsequent UHRF1 inhibition. UHRF1 downregulation results in the






























Fig. 3 Role of CD47/NF-ĸB pathway in UHRF1 regulation. a. CD47 activation induces IĸBα phosphorylation allowing the translocation of the
active NF-ĸB complex (p50 or p65) into nucleus to activate the UHRF1 gene with subsequent p16INK4A repression and enhanced cell proliferation.
b. Blocking CD47 function inhibits NF‐κB transactivation leading to decrease in binding of NF‐κB components (p50 or p65) to UHRF1 promoter
inducing cell proliferation inhibition via p16INK4A reactivation
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cycle arrest and cell proliferation inhibition [104]. Inter-
estingly, DNA ChIP assay showed that Sp1 binds to a
specific site on UHRF1 promoter indicating that T3
regulates the expression of UHRF1 through the tran-
scription factor Sp1 [104]. UHRF1 and Sp1 mRNA levels
were also increased in hepatocellular carcinoma HCCs
patient tissues compared to adjacent normal tissues in
parallel with a decrease in the expression of TRα1 and
p21 [104]. UHRF1 overexpression in HepG2 counter-
acted the T3-induced p21 overexpression, G0/G1 cell
cycle arrest and cell proliferation inhibition allowing cell
passage to G2/M phase [104]. Taken together, these
findings show that T3/TRα1 pathway is involved in the
regulation of UHRF1 expression in liver cancer through
the transcription factor Sp1 (Fig. 4). This suggests that
defects in T3/TR pathway in cancer cells result in
UHRF1 overexpression through increasing of Sp1 bind-
ing to its promoter with subsequent cell proliferation
and metastasis (Fig. 4a). Exposure of cancer cells to T3
induces a decrease in Sp1 binding to UHRF1 promoter
causing its inactivation and subsequent p21 reactivation
and cell proliferation inhibition (Fig. 4b).
Inhibitors of UHRF1 and its signalling pathways
In vitro and in vivo studies have shown that a drug-
induced inhibition of UHRF1 activity or expression leads
to the reactivation of several tumor suppressor genes
enabling cancer cells to undergo apoptosis [8, 29]. So far,
only one direct inhibitor of UHRF1 has recently been re-
ported [24]. Indeed, through a tandem virtual screening,
a uracil derivative (NSC232003, Fig. 5), was described as a
putative compound able to fit within the 5-methylcytosine
binding pocket of the UHRF1 SRA domain. Interestingly,
NSC232003 induces a global DNA hypomethylation prob-
ably through prevention of hemi-methylated DNA recog-
nition by the SRA domain concomitantly to a disruption
of UHRF1/DNMT1 interactions [24]. However, further
investigations on this compound must be performed to
check its capacity to reactivate silenced tumor suppressor
genes through a UHRF1-dependent mechanism.
While, as stated above, the uracil derivative is the sole
direct inhibitor, several inhibitors of the signaling path-
ways regulating UHRF1 expression are documented.
UHRF1 expression was shown to be targeted by the nat-
ural product naphthazarin (Fig. 5) [105]. Naphthazarin
induced cell proliferation inhibition and apoptosis of
MCF-7 cells exposed to radiation through decreased
binding of UHRF1, DNMT1 and HDAC1 to p21CIP/WAF1
promoter [105]. In the same context, shikonin (Fig. 5), a
natural naphthoquinone isolated from the Chinese trad-
itional medicine Zi Cao (purple gromwell), has been
shown to induce apoptosis in MCF-7 and HeLa cells,
this effect was associated with a decrease in UHRF1
binding to p16INK4A promoter [106]. We have shown
that TQ (Fig. 5) inhibits cell proliferation and induces
apoptosis of Jurkat cells through p73 and caspase 3
upregulation and UHRF1 downregulation [63]. In accord-
ance with these studies, we have also shown that treating
B16F10 murine melanoma cells with curcumin induced a

















Inhibition of Cell growth and metastasis
a
TR-mutated cancer cells 
b
TR-expression cancer cells 
Fig. 4 Schematic model of the role of TRα1/Sp1 pathway in the regulation of UHRF1. a. Abnormalities in T3/TRa1 pathway result in increasing
of Sp1 binding to UHRF1 promoter causing its activation. UHRF1 overexpression suppresses the expression of p21 gene with subsequent cell
proliferation and metastasis. b. Exposure of TR-expressing cells to T3 induces a decrease in Sp1 binding to UHRF1 promoter causing its inactivation.
UHRF1 repression results in p21 reactivation with subsequent inhibition of cell proliferation and metastasis
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cell cycle arrest and apoptosis [107]. EGCG (Fig. 5)
appears to take the same pathway to achieve the induction
of apoptosis in Jurkat cells, i.e. UHRF1 downregulation
and p16INK4A upregulation [32]. Although, several studies
[37, 44, 108, 109] tend to show that reactivation of
tumor suppressor gene involves a UHRF1 downregulation-
dependent promoter demethylation, the contribution of
other mechanisms are not excluded. Indeed, UHRF1 has
been suggested to be a main player in the reactivation of
the tumor suppressor gene Pax1 (Paired box gene1) in
several cancer cell lines in response to curcumin and
resveratrol through a mechanism involving histone methy-
lation and deacetylation rather than a DNA methylation-
dependent process [110].
Other natural compounds, such as anisomycin and
luteolin (Fig. 5), have been also reported to efficiently
affect UHRF1 expression [111, 112]. Nevertheless, the
mechanism of UHRF1 downregulation induced by natural
compounds that target the signaling pathways of UHRF1
expression remains to be deciphered, but might involve
the proteasome pathway. Indeed, for instance, the small
molecule 17-AAG, a HSP90 inhibitor has been shown to
induce UHRF1 ubiquitination leading to its degradation
through proteasome-dependent pathway [113].
Conclusion
The overexpression of the anti-apoptotic UHRF1 has
been shown to coordinate the epigenetic silencing of
several TSGs in many human haematological and solid
cancers causing apoptosis inhibition. Via its structural
domains, UHRF1 interacts with several proteins involved
in the silencing of TSGs including DNMT1, HDAC1,
G9a and Suv39H1 which make it a strong candidate to
be the driver of this macro-protein complex to ensure
the transmission of epigenetic code from a mother
cancer cell to daughter cells during cell proliferation.
The large quantities of UHRF1 produced in cancers
could be result from abnormalities in the upstream regu-
latory mechanisms of UHRF1. This review highlighted
the signalling pathways underlying UHRF1 regulation in
cancer cells. Thus, understanding the molecular mecha-
nisms involved in UHRF1 regulation will allow us to find
new targets in order to inhibit the expression of UHRF1
allowing cancer cells to undergo apoptosis through a re-
expression of tumor suppressor genes. As an interesting
perspective in the field of cancer therapy, we have
recently identified an inhibitor of UHRF1 (a uracil
derivative) that targets the SRA domain with subsequent
impact on DNMT1/UHRF1 interactions and decrease in
global DNA methylation [24].
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